OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +16

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Jennifer K. Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine · 2018 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +14

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation

Bella Kaufman, Ronnie Shapira‐Frommer, Rita K. Schmutzler et al. · Journal of Clinical Oncology · 2014 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

Fergus J. Couch, Steven N. Hart, Priyanka Sharma et al. · Journal of Clinical Oncology · 2014 · 684 citations · Full text

Life Sciences, Genetics, Oncology +17

Prevalence and Predictors of <i>BRCA1</i> and <i>BRCA2</i> Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years

Kathleen E. Malone, Janet R. Daling, David R. Doody et al. · Cancer Research · 2006 · 376 citations · Full text

Life Sciences, Genetics, Oncology +17